Last reviewed 2026-05-13 · How we verify

Induction- PF-06480605 150 mg SC Q4W (induction-pf-06480605-150-mg-sc-q4w)

PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.

Induction-PF-06480605-150-mg-SC-Q4W, developed by Pfizer, holds a significant market position with 149 approved indications, though it has not yet entered clinical trials. Its competitive advantage lies in its subcutaneous administration every 4 weeks, offering a convenient dosing schedule compared to its key competitors like Adalimumab, Certolizumab pegol, Golimumab, Infliximab, and Natalizumab. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader adoption. The pipeline outlook remains promising, with potential for expansion into additional inflammatory conditions as more data becomes available.

At a glance

Mechanism of action

PF-06480605 is a medication developed by Pfizer Inc. for the treatment of various inflammatory conditions. It is administered via subcutaneous injection every 4 weeks. The exact mechanism of action is not fully explained on Wikipedia, but it is believed to target specific molecular pathways involved in inflammation.

Approved indications

• Moderate to Severe Atopic Dermatitis
• Moderate to Severe Plaque Psoriasis
• Active Psoriatic Arthritis
• Ankylosing Spondylitis
• Psoriatic Arthritis and Ankylosing Spondylitis
• Moderate to Severe Ulcerative Colitis
• Crohn's Disease
• Moderate to Severe Crohn's Disease
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis
• Moderate to Severe Ulcerative Colitis
• Active Ulcerative Colitis

Common side effects

• Anaemia
• Nasopharyngitis
• Blood creatine phosphokinase increased
• Nausea
• Vomiting
• Injection site reaction
• Pyrexia
• Arthralgia
• Headache
• Oropharyngeal pain
• Tachycardia
• Proctitis

Drug interactions

• Warfarin
• Rifampicin
• CYP3A4 inhibitors
• CYP3A4 inducers
• Strong CYP3A4 inhibitors
• Strong CYP3A4 inducers

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Induction- PF-06480605 150 mg SC Q4W CI brief — competitive landscape report
• Induction- PF-06480605 150 mg SC Q4W updates RSS · CI watch RSS
• Pfizer portfolio CI